# Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

> **NCT00948909** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 274 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** ABT-126
- **DRUG:** donepezil

## Key facts

- **NCT ID:** NCT00948909
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2013-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948909, "Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00948909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*